BeOne Medicines AG (ONC)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $47.58B
Last updated: Nov 17, 2026 at 11:05 AM ET
BeOne Medicines AG (ONC) P/E Ratio & Valuation Multiples
BeOne Medicines AG (ONC) trades at 50.0x trailing earnings and 18.7x sales. Its P/S of 18.7x is below its 5-year median of 52.1x. Its forward P/E is 36.5x. The median P/E across 7 similar companies is 30.0x.
Current Multiples
Its forward P/E is below its trailing P/E, which implies earnings per share about 37.0% higher over the next year. Its free cash flow yield is 1.3%.
| Multiple | Value |
|---|---|
| P/E (trailing) | 50.0x |
| Forward P/E | 36.5x |
| Price to sales | 18.7x |
| Price to book | 8.3x |
| EV/EBITDA | 73.2x |
| Price to FCF | 80.0x |
| EV/FCF | 72.2x |
| PEG | 0.7 |
| FCF yield | 1.3% |
Historical Medians
Against its 10-year medians, its P/S is 83.0% below 110.3x and its P/B is 79.8% below 41.0x.
| Multiple | Current | 5-year median | 10-year median |
|---|---|---|---|
| P/S | 18.7x | 52.1x | 110.3x |
| P/B | 8.3x | 40.1x | 41.0x |
Valuation History
Over the 9 of the 10 year ends shown that have a P/S, its P/S ranged from 36.7x in 2024 to 950.4x in 2016.
| Year end | Price | P/S | P/B |
|---|---|---|---|
| 2025 | $303.81 | 45.8x | 55.3x |
| 2024 | $184.71 | 36.7x | 43.0x |
| 2023 | $180.36 | 55.2x | 37.7x |
| 2022 | $219.94 | 108.6x | 35.9x |
| 2021 | $270.93 | 142.0x | 26.7x |
| 2020 | $258.39 | 483.0x | 39.6x |
| 2019 | $165.76 | 159.6x | 72.8x |
| 2018 | $140.26 | 264.0x | 32.7x |
| 2017 | $97.72 | N/A | 42.3x |
| 2016 | $30.36 | 950.4x | 23.7x |
P/E history is shown only for companies that report in US dollars.
GNG Valuation
| GNG view | Overvalued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About ONC
What is ONC's forward P/E ratio?
BeOne Medicines AG has a forward P/E ratio of 36.5x.
Is ONC stock overvalued?
GNG's valuation label for ONC is Overvalued. Its P/E of 50.0x compares with a median of 30.0x across 7 similar companies.
What is ONC's price to sales ratio?
BeOne Medicines AG has a price to sales ratio of 18.7x.
What is ONC's PEG ratio?
BeOne Medicines AG has a PEG ratio of 0.7.
ONC pages: Overview, Valuation, Competitors